Efficacy of class ia antiarrhythmic drugs in converting atrial fibrillation unassociated with organic heart disease and their relation to atrial electrophysiologic characteristics

1994 ◽  
Vol 74 (3) ◽  
pp. 282-283 ◽  
Author(s):  
Akira Fujiki ◽  
Shigeki Yoshida ◽  
Masanao Tani ◽  
Hiroshi Inoue
2002 ◽  
Vol 13 (6) ◽  
pp. 571-577 ◽  
Author(s):  
TSU-JUEY WU ◽  
RAHUL N. DOSHI ◽  
HSUN-LUN A. HUANG ◽  
CARLOS BLANCHE ◽  
ROBERT M. KASS ◽  
...  

2006 ◽  
Vol 96 (2) ◽  
pp. 103-108 ◽  
Author(s):  
Thomas Kleemann ◽  
Torsten Becker ◽  
Klaus Dönges ◽  
Margit Vater ◽  
Bern Gut ◽  
...  

2020 ◽  
Author(s):  
Xiaoyu Pan ◽  
Zaiwei Zhang

Abstract OBJECTIVE:Atrial fibrillation (AF) is one of the most common arrhythmias, which is caused by a number of minorring disorders caused by the heart owner's guide. It is noted in almost all organic heart disease and can also occur in non-organic heart disease,causing serious complications, such as heart failure and arterial embolism, seriously threaten people's health.Atrial fibrillation can cause serious complications, such as heart failure and arterial embolism, which seriously threaten people's health. Clinically, according to the characteristics of atrial fibrillation, atrial fibrillation is divided into paroxysmal atrial fibrillation,persistent atrial fibrillation, permanent atrial fibrillation (cannot be converted to sinus rhythm).Among them, persistent atrial fibrillation poses the greatest threat to people's health.So the main purpose of this study is to identify the differential genes in patients with permanent atrial fibrillation. MATERIALS AND METHODS:To explore potential differential genes for permanent atrial fibrillation, we analyzed three microarray datasets GSE2240 derived from the Gene Expression Omnibus (GEO) database. We used the“limma”function package of R software to screen differentially expressed genes(DEGs), and used the“pheatmap”function package to construct heatmaps for the screened differential genes.Visualization and Integration Discovery (DAVID) ,Cytoscape ,BMKcloud and String platforms were utilized for Genome Ontology (GO) analysis,Kyoto Encyclopedia of Genes and Genomes (KEGG) analysis , PPI(protein-proteinInteraction) network analysis ,module analysis,and identification hub genes based on the selected differential genes.RESULTS:74 DEGs in total were identified, including 41 up- and 33 downregulated genes. These DEGs were mainly enriched in PI3K-Akt signaling pathway ,cGMP-PKG signaling pathway, Focal adhesion, and so on. The module analysis filtered out 12 key genes, including PRL, CREB1, AGO2, NAMPT, IGFBP2, FGF7, ANGPT2, SYT13, NRXN1, AQP4, TCEAL2, and CPLX1. 2 Hub genes were identified, including IGFBP2, and FGF7.CONCLUSIONS:IGFBP2 and FGF7 were identified as Hub genes of AF, which helped us to understand more deeply the pathophysiological mechanism of AF.


2009 ◽  
Vol 5 (1) ◽  
pp. 36
Author(s):  
Philippe Chevalier ◽  

Atrial fibrillation (AF) is the most common arrhythmia, with incidence increasing with age and a ranging severity of symptoms. The arrhythmia, perpetuated from electrical, functional and structural remodelling by AF itself, can ultimately lead to increased morbidity and mortality. Emerging evidence appears to support the initiation of rhythm control, particularly early on in the disease course. Antiarrhythmic drugs have proved useful in inducing and maintaining cardioversion, but treatment varies depending on the degree of structural heart disease. Drug trials and selection of therapy have historically focused largely on cardiac safety. Class Ic drugs have demonstrated safety and efficacy in patients with little to no structural heart disease, yet their use continues to be superseded by the use of other drugs, especially amiodarone, which carries significant risks of extracardiac effects and end-organ toxicities. This article discusses the role of sinus rhythm control and antiarrhythmic drugs in AF, with an emphasis on patients exhibiting no or minimal structural heart disease and the importance of selecting an appropriate antiarrhythmic drug, taking into account arrhythmia burden, presence of concurrent cardiovascular disease and severity and, most importantly, the safety of the drug therapy.


1998 ◽  
Vol 32 (4) ◽  
pp. 1040-1047 ◽  
Author(s):  
Miralem Pasic ◽  
Michele Musci ◽  
Henryk Siniawski ◽  
Barbara Edelmann ◽  
Takeo Tedoriya ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document